Phase 3, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Treatment of C3G or IC-MPGN
Access Resources
Efficacy and safety of 12-week pegcetacoplan in kidney transplant recipients with recurrent C3G or primary IC-MPGN: 12-week results from the NOBLE study
Access Resources
The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.
The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available fo rthe uses being investigated.
If you are a Healthcare Professional licensed to practice in the United States
If you are a Healthcare Professional licensed to practice in Canada
If you are a Healthcare Professional licensed to practice in Europe
If you are a Healthcare Professional licensed to practice in Australia